Serum hepcidin-25 levels reflect the presence of bacteremia in patients with systemic inflammatory response syndrome

Hiroaki Wakakuri, MD1, Tatsuya Degawa, MD2, Taro Saigusa, MD2, Makoto Suzaki, MD2, Sonoko Kirinoki, MD2, Hideya Hyodo, MD1, Toshihiko Ohara, MD1, Makoto Kawai, MD1, Masahiro Yasutake, MD3, 1Nippon Medical School Hospital, Tokyo, Japan; 2Nippon Medical School, Tokyo, Japan; 3Nippon Medical School Hospital, Tokyo Japan, Tokyo, Japan

Meeting: Hospital Medicine 2018; April 8-11; Orlando, Fla.

Abstract number: 149

Categories: Hospital Medicine 2018, Outcomes Research, Research

Keywords: , ,

Background: Hepcidin-25 is a liver-derived key peptide hormone that regulates iron homeostasis in humans. Recent studies have suggested that hepcidin also play a key role in host-defense mechanism. Iron is essential for the survival and growth of bacteria. When the bacteria infect macrophages, macrophages release a number of cytokines including interleukin-6, which increase production of hepcidin in the hepatocytes. This up-regulation of hepcidin leads to iron depletion and inhibition of bacterial growth. The aim of this study is to investigate serum hepcidin-25 levels and their relationship with the severity of inflammation and bacteremia in patients with systemic inflammatory response syndrome (SIRS).

Methods: Of all patients who were admitted to our department of general medicine between August 1, 2015 and August 31, 2017, 113 consecutive patients (aged 63.4±21, male 50, female 63) with 2 or more SIRS criteria were enrolled. We measured complete blood cell count, hepcidin-25, iron, iron-binding capacity, ferritin, blood urea nitrogen, creatinine, albumin, and C-reactive protein at day 1, 2 and 3 after admission. The patients were divided into 3 groups for comparison: Bacteremia group (27 patients), Bacterial infection with negative blood culture group (60 patients), and Non-bacterial infection group (26 patients).

Results: Hepcidin-25 levels on day1 were 167±120 in patients with 2 criteria, 190±97 in those with 3, and 211±100 ng/ml in those with 4, respectively (P=0.442). There was significant difference in the maximum hepcidin-25 levels between the bacteremia group, the bacterial infection with negative blood cultures group, and the non-bacterial group (252±122 vs 187±99 vs 175±132 ng/ml, P<0.05). The hepcidin-25 levels of the bacteremia group were significantly higher than those of the other groups.

Conclusions: Our findings suggest that serum hepcidin-25 levels have not significant impact on the severity of inflammation, but that they may contribute to determining bacteremia in SIRS patients.

To cite this abstract:

Wakakuri, H; Degawa, T; Saigusa, T; Suzaki, M; Kirinoki, S; Hyodo, H; Ohara, T; Kawai, M; Yasutake, M. Serum hepcidin-25 levels reflect the presence of bacteremia in patients with systemic inflammatory response syndrome. Abstract published at Hospital Medicine 2018; April 8-11; Orlando, Fla. Abstract 149. https://www.shmabstracts.com/abstract/serum-hepcidin-25-levels-reflect-the-presence-of-bacteremia-in-patients-with-systemic-inflammatory-response-syndrome/. Accessed January 28, 2020.

« Back to Hospital Medicine 2018; April 8-11; Orlando, Fla.